Search

Your search keyword '"DeAngelo, Daniel J"' showing total 2,109 results
Start Over Author "DeAngelo, Daniel J"
2,109 results on '"DeAngelo, Daniel J"'

1. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes

Author

Jann, Johann-Christoph, Hergott, Christopher B., Winkler, Marisa, Liu, Yiwen, Braun, Benjamin, Charles, Anne, Copson, Kevin M., Barua, Shougat, Meggendorfer, Manja, Nadarajah, Niroshan, Shimony, Shai, Winer, Eric S., Wadleigh, Martha, Stone, Richard M., DeAngelo, Daniel J., Garcia, Jacqueline S., Haferlach, Torsten, Lindsley, R. Coleman, Luskin, Marlise R., Stahl, Maximilian, and Tothova, Zuzana

Published
2024
Full Text
View/download PDF

3. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Author

Cortes, Jorge E., Sasaki, Koji, Kim, Dong-Wook, Hughes, Timothy P., Etienne, Gabriel, Mauro, Michael J., Hochhaus, Andreas, Lang, Fabian, Heinrich, Michael C., Breccia, Massimo, Deininger, Michael, Goh, Yeow Tee, Janssen, Jeroen J.W.M., Talpaz, Moshe, de Soria, Valle Gomez Garcia, le Coutre, Philipp, DeAngelo, Daniel J., Damon, Andrea, Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, and Rea, Delphine

Published
2024
Full Text
View/download PDF

4. Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen

Author

Shimony, Shai, Raman, Hari S., Flamand, Yael, Keating, Julia, Paolino, Jonathan D., Valtis, Yannis K., Place, Andrew E., Silverman, Lewis B., Sallan, Stephen E., Vrooman, Lynda M., Brunner, Andrew M., Neuberg, Donna S., Galinsky, Ilene, Garcia, Jacqueline S., Winer, Eric S., Wadleigh, Martha, Stone, Richard M., Connors, Jean M., DeAngelo, Daniel J., and Luskin, Marlise R.

Published
2024
Full Text
View/download PDF

5. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Author

Shimony, Shai, Bewersdorf, Jan Philipp, Shallis, Rory M., Liu, Yiwen, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron D., Stein, Eytan M., Marcucci, Guido, Lindsley, R. Coleman, Chen, Evan C., Ramos Perez, Jorge, Stein, Anthony, DeAngelo, Daniel J., Neuberg, Donna S., Stone, Richard M., Ball, Brian, and Stahl, Maximilian

Published
2024
Full Text
View/download PDF

6. Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Author

Jabbour, Elias, Apperley, Jane, Cortes, Jorge, Rea, Delphine, Deininger, Michael, Abruzzese, Elisabetta, Chuah, Charles, DeAngelo, Daniel J., Hochhaus, Andreas, Lipton, Jeffrey H., Mauro, Michael, Nicolini, Franck, Pinilla-Ibarz, Javier, Rosti, Gianantonio, Rousselot, Philippe, Shah, Neil P., Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, and Kantarjian, Hagop

Published
2024
Full Text
View/download PDF

8. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Author

Jabbour, Elias, Apperley, Jane, Cortes, Jorge, Rea, Delphine, Deininger, Michael, Abruzzese, Elisabetta, Chuah, Charles, DeAngelo, Daniel J., Hochhaus, Andreas, Lipton, Jeffrey H., Mauro, Michael, Nicolini, Franck, Pinilla-Ibarz, Javier, Rosti, Gianantonio, Rousselot, Philippe, Shah, Neil P., Talpaz, Moshe, Vorog, Alexander, Ren, Xiaowei, and Kantarjian, Hagop

Published
2024
Full Text
View/download PDF

10. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Author

Bewersdorf, Jan Philipp, Shimony, Shai, Shallis, Rory M., Liu, Yiwen, Berton, Guillaume, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron D., Stein, Eytan M., Marcucci, Guido, Bystrom, Rebecca P., Lindsley, R. Coleman, Chen, Evan C., Ramos Perez, Jorge, Stein, Anthony, Pullarkat, Vinod, Aldoss, Ibrahim, DeAngelo, Daniel J., Neuberg, Donna S., Stone, Richard M., Garciaz, Sylvain, Ball, Brian, and Stahl, Maximilian

Published
2024
Full Text
View/download PDF

11. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

Author

Zhao, Yaqi, Laird, A. Douglas, Roberts, Kathryn G., Yafawi, Rolla, Kantarjian, Hagop, DeAngelo, Daniel J., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan, Jabbour, Elias, Cassaday, Ryan D., Loyd, Melanie R., Olsen, Scott, Neale, Geoffrey, Liu, Xueli, Vandendries, Erik, Advani, Anjali, and Mullighan, Charles G.

Published
2024
Full Text
View/download PDF

13. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Author

Zeidan, Amer M, DeAngelo, Daniel J, Palmer, Jeanne, Seet, Christopher S, Tallman, Martin S, Wei, Xin, Raymon, Heather, Sriraman, Priya, Kopytek, Stephan, Bewersdorf, Jan Philipp, Burgess, Michael R, Hege, Kristen, and Stock, Wendy

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Trials and Supportive Activities, Pediatric, Cancer, Clinical Research, Hematology, Pediatric Research Initiative, Pediatric Cancer, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adult, Aged, Aged, 80 and over, Animals, Female, Humans, Male, Mice, Middle Aged, Antineoplastic Agents, Immunological, CD47 Antigen, Leukemia, Myeloid, Acute, Macaca fascicularis, Maximum Tolerated Dose, Mice, SCID, Myelodysplastic Syndromes, Neoplasm Recurrence, Local, Safety, SIRP alpha, IgG4PE, Macrophages, Hematological cancer, SIRPα, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

CC-90002 is an anti-CD47 antibody that inhibits CD47-SIRPα interaction and enables macrophage-mediated killing of tumor cells in hematological cancer cell lines. In this first clinical, phase 1, dose-escalation and -expansion study (CC-90002-AML-001; NCT02641002), we evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). CC-90002 was administered in escalating doses of 0.1-4.0 mg/kg, using a modified 3 + 3 design. Primary endpoints included dose-limiting toxicities (DLTs), non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended phase 2 dose. Secondary endpoints included preliminary efficacy, pharmacokinetics, and presence/frequency of anti-drug antibodies (ADAs). Between March 2016 and July 2018, 28 patients were enrolled (24 with AML and 4 with MDS) at 6 sites across the USA. As of July 18, 2018, all patients had discontinued, mainly due to death or progressive disease. The most common treatment-emergent adverse events were diarrhea (46.4%), thrombocytopenia (39.3%), febrile neutropenia (35.7%), and aspartate aminotransferase increase (35.7%). Four patients experienced DLTs (1 patient had grade 4 disseminated intravascular coagulation and grade 5 cerebral hemorrhage, 1 had grade 3 purpura, 1 had grade 4 congestive cardiac failure and grade 5 acute respiratory failure, and another had grade 5 sepsis). The NTD and MTD were not reached. No objective responses occurred. CC-90002 serum exposure was dose-dependent. ADAs were present across all doses, and the proportion of ADA-positive patients in cycle 1 increased over time. Despite no unexpected safety findings, the CC-90002-AML-001 study was discontinued in dose escalation for lack of monotherapy activity and evidence of ADAs. However, as other anti-CD47 agents in clinical trials are showing promising early results for AML and MDS, understanding preclinical and clinical differences between individual agents in this class will be of high importance.

Published
2022

14. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Author

Shah, Bijal D, Ghobadi, Armin, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Cassaday, Ryan D, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O’Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Park, Jae H, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick, Jeyakumar, Deepa, Dong, Jinghui, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra C, Faghmous, Imi, Masouleh, Behzad Kharabi, and Houot, Roch

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Pediatric Cancer, Stem Cell Research, Hematology, Pediatric Research Initiative, Clinical Trials and Supportive Activities, Childhood Leukemia, Cancer, Pediatric, Humans, Adult, Immunotherapy, Adoptive, Retrospective Studies, Historically Controlled Study, Recurrence, Receptors, Chimeric Antigen, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, B-precursor acute lymphoblastic leukemia, Brexucabtagene autoleucel, CAR T-cell therapy, KTE-X19, SCHOLAR-3, ZUMA-3, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

BackgroundBrexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study results. We report updated ZUMA-3 outcomes with longer follow-up and an extended data set along with contextualization of outcomes to historical standard of care.MethodsAdults with R/R B-ALL received a single infusion of KTE-X19 (1 × 106 CAR T cells/kg). Long-term post hoc subgroup assessments of ZUMA-3 were conducted. Outcomes from matched patients between historical clinical trials and ZUMA-3 patients were assessed in the retrospective historical control study SCHOLAR-3.ResultsAfter 26.8-months median follow-up, the overall complete remission (CR) rate (CR + CR with incomplete hematological recovery) among treated patients (N = 55) in phase 2 was 71% (56% CR rate); medians for duration of remission and overall survival (OS) were 14.6 and 25.4 months, respectively. Most patients responded to KTE-X19 regardless of age or baseline bone marrow blast percentage, but less so in patients with > 75% blasts. No new safety signals were observed. Similar outcomes were observed in a pooled analysis of phase 1 and 2 patients (N = 78). In SCHOLAR-3, the median OS for treated patients from ZUMA-3 (N = 49) and matched historical controls (N = 40) was 25.4 and 5.5 months, respectively.ConclusionsThese data, representing the longest follow-up of CAR T-cell therapy in a multicenter study of adult R/R B-ALL, suggest that KTE-X19 provides a clinically meaningful survival benefit with manageable toxicity in this population.Trial registrationNCT02614066.

Published
2022

15. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Author

Daver, Naval G, Montesinos, Pau, DeAngelo, Daniel J, Wang, Eunice S, Papadantonakis, Nikolaos, Todisco, Elisabetta, Sweet, Kendra L, Pemmaraju, Naveen, Lane, Andrew A, Torres-Miñana, Laura, Thompson, James E, Konopleva, Marina Y, Sloss, Callum M, Watkins, Krystal, Bedse, Gaurav, Du, Yining, Malcolm, Kara E, Zweidler-McKay, Patrick A, and Kantarjian, Hagop M

Published
2024
Full Text
View/download PDF

16. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Author

Garcia, Jacqueline S., Kim, Haesook T., Murdock, H. Moses, Ansuinelli, Michela, Brock, Jennifer, Cutler, Corey S., Gooptu, Mahasweta, Ho, Vincent T., Koreth, John, Nikiforow, Sarah, Romee, Rizwan, Shapiro, Roman, DeAngelo, Daniel J., Stone, Richard M., Bat-Erdene, Denbaa, Ryan, Jeremy, Contreras, Manuel E., Fell, Geoffrey, Letai, Anthony, Ritz, Jerome, Lindsley, R. Coleman, Soiffer, Robert J., and Antin, Joseph H.

Published
2024
Full Text
View/download PDF

17. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Author

Lane, Andrew A., Garcia, Jacqueline S., Raulston, Evangeline G., Garzon, Jada L., Galinsky, Ilene, Baxter, Emilie W., Leonard, Rebecca, DeAngelo, Daniel J., Luskin, Marlise R., Reilly, Christopher R., Stahl, Maximilian, Stone, Richard M., Vedula, Rahul S., Wadleigh, Martha M., Winer, Eric S., Mughal, Tariq, Brooks, Christopher, Gupta, Ira V., Stevenson, Kristen E., Neuberg, Donna S., Ren, Siyang, Keating, Julia, Konopleva, Marina, Stein, Anthony, and Pemmaraju, Naveen

Published
2024
Full Text
View/download PDF

20. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow

Author

Sadigh, Sam, DeAngelo, Daniel J., Garcia, Jacqueline S., Hasserjian, Robert P., Hergott, Christopher B., Lane, Andrew A., Lovitch, Scott B., Lucas, Fabienne, Luskin, Marlise R., Morgan, Elizabeth A., Pinkus, Geraldine S., Pozdnyakova, Olga, Rodig, Scott J., Shanmugam, Vignesh, Tsai, Harrison K., Winer, Eric S., Zemmour, David, and Kim, Annette S.

Published
2024
Full Text
View/download PDF

21. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Author

Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias, and Lang, Fabian

Published
2023
Full Text
View/download PDF

23. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

Author

Stock, Wendy, Martinelli, Giovanni, Stelljes, Matthias, DeAngelo, Daniel J, Gökbuget, Nicola, Advani, Anjali S, O’Brien, Susan, Liedtke, Michaela, Merchant, Akil A, Cassaday, Ryan D, Wang, Tao, Zhang, Hui, Vandendries, Erik, Jabbour, Elias, Marks, David I, and Kantarjian, Hagop M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Pediatric Cancer, Cancer, Rare Diseases, Hematology, Pediatric, Transplantation, Childhood Leukemia, Regenerative Medicine, Pediatric Research Initiative, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Inotuzumab Ozogamicin, Neoplasm, Residual, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, acute lymphoblastic leukemia, efficacy, hematopoietic stem cell transplantation, inotuzumab ozogamicin, Philadelphia chromosome, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundPatients with relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options.MethodsThe efficacy of inotuzumab ozogamicin (InO), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, was evaluated in R/R ALL patients in the phase 1/2 study 1010 (NCT01363297) and open-label, randomized, phase 3 study 1022 (INO-VATE; NCT01564784). This analysis focused specifically on Ph+ R/R ALL patients. In study 1022, Ph+ patients were randomly assigned 1:1 to InO (n = 22) or standard intensive chemotherapy (SC) (n = 27) and 16 Ph+ patients in study 1010 received InO.ResultsIn study 1022, rates of complete remission/complete remission with incomplete hematologic recovery (CR/CRi) and minimal residual disease (MRD) negativity (patients achieving CR/CRi) were higher with InO (CR/CRi = 73%; MRD = 81%) versus SC (CR/CRi = 56%; MRD = 33%). The corresponding rates in study 1010 were 56% (CR/CRi) and 100% (MRD). The hematopoietic stem cell transplantation (HSCT) rate in study 1022 was 41% versus 19% for InO versus SC; however, there was no benefit in overall survival (median OS: 8.7 vs 8.4 months; hazard ratio, 1.17 [95% CI, 0.64-2.14]). The probability of being event-free (progression-free survival) at 12 months was greater with InO versus SC (20.1% vs 4.8%).ConclusionGiven the substantial improvement in responses and rates of HSCT, InO is an important treatment option for patients with R/R Ph+ ALL. Future studies need to consider better characterization of disease characteristics, more sensitive MRD measurements, MRD-directed therapy before HSCT, and potentially combination therapies, including tyrosine kinase inhibitors.

Published
2021

24. Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021

Author

Mughal, Tariq I, Psaila, Bethan, DeAngelo, Daniel J, Saglio, Giuseppe, Van Etten, Richard A, and Radich, Jerald P

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Good Health and Well Being, Humans, Molecular Biology, Myeloproliferative Disorders, Neoplasms, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Published
2021

28. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

Author

DeAngelo, Daniel J, Advani, Anjali S, Marks, David I, Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, Jabbour, Elias, Merchant, Akil, Wang, Tao, Vandendries, Erik, Neuhof, Alexander, Kantarjian, Hagop, and O’Brien, Susan

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Hematology, Childhood Leukemia, Transplantation, Orphan Drug, Rare Diseases, Cancer, Pediatric Research Initiative, Clinical Research, Pediatric, Pediatric Cancer, Good Health and Well Being, Acute Disease, Adult, Antineoplastic Agents, Immunological, Bone Marrow, Humans, Inotuzumab Ozogamicin, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy and safety of inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC) among R/R ALL patients with low, moderate, or high disease burden, respectively, defined as bone marrow blasts (BMB) 90% (n = 30 vs. 30). Patients in the InO vs. SC arm with low, moderate, and high BMB%, respectively, had improved rates of complete remission/complete remission with incomplete hematologic recovery (74% vs. 46% [p = 0.0022], 75 vs. 27% [p

Published
2020

31. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Author

Reiter, Andreas, Gotlib, Jason, Álvarez-Twose, Iván, Radia, Deepti H., Lübke, Johannes, Bobbili, Priyanka J., Wang, Aolin, Norregaard, Chelsea, Dimitrijevic, Saša, Sullivan, Erin, Louie-Gao, Melinda, Schwaab, Juliana, Galinsky, Ilene A., Perkins, Cecelia, Sperr, Wolfgang R., Sriskandarajah, Priya, Chin, Andi, Sendhil, Selvam R., Duh, Mei Sheng, Valent, Peter, and DeAngelo, Daniel J.

Published
2022
Full Text
View/download PDF

32. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Author

Kantarjian, Hagop M, DeAngelo, Daniel J, Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan M, Jabbour, Elias, Wang, Tao, White, Jane Liang, Sleight, Barbara, Vandendries, Erik, and Advani, Anjali S

Subjects
Clinical Trials and Supportive Activities, Transplantation, Stem Cell Research, Rare Diseases, Cancer, Hematology, Pediatric, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adolescent, Adult, Aged, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Hepatic Veno-Occlusive Disease, Humans, Inotuzumab Ozogamicin, Male, Middle Aged, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Progression-Free Survival, Pulmonary Veno-Occlusive Disease, Recurrence, Remission Induction, Standard of Care, Survival Rate, Young Adult, acute lymphoblastic leukemia, adults, hematopoietic stem cell transplantation, hepatic veno-occlusive disease, inotuzumab ozogamicin, remission induction, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundInotuzumab ozogamicin (InO) is an antibody-drug conjugate used for adults with relapsed/refractory B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). The INotuzumab Ozogamicin trial to inVestigAte Tolerability and Efficacy (INO-VATE) previously reported improved outcomes with InO versus standard-of-care (SoC) chemotherapy. This article reports the final INO-VATE results (≥2 years of follow-up) and additional analyses of patient characteristics associated with improved outcomes.MethodsBetween August 27, 2012, and January 4, 2015, this multicenter, parallel, open-label, phase 3 trial randomized 326 adults with relapsed/refractory ALL to InO (n = 164) or SoC (n = 162); 307 received 1 or more doses of the study drug (164 in the InO arm and 143 in the SoC arm).ResultsThe complete remission (CR)/complete remission with incomplete hematologic recovery (CRi) rate was higher with InO versus SoC (73.8% vs 30.9%; 1-sided P

Published
2019

37. Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy

Author

Versluis, Jurjen, Pandey, Manu, Flamand, Yael, Haydu, J. Erika, Belizaire, Roger, Faber, Mark, Vedula, Rahul S., Charles, Anne, Copson, Kevin M., Shimony, Shai, Rozental, Alon, Bendapudi, Pavan K., Wolach, Ofir, Griffiths, Elizabeth A., Thompson, James E., Stone, Richard M., DeAngelo, Daniel J., Neuberg, Donna, Luskin, Marlise R., Wang, Eunice S., and Lindsley, R. Coleman

Published
2022
Full Text
View/download PDF

38. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms

Author

Van Egeren, Debra, Kamaz, Baransel, Liu, Shichen, Nguyen, Maximilian, Reilly, Christopher R., Kalyva, Maria, DeAngelo, Daniel J., Galinsky, Ilene, Wadleigh, Martha, Winer, Eric S., Luskin, Marlise R., Stone, Richard M., Garcia, Jacqueline S., Hobbs, Gabriela S., Michor, Franziska, Cortes-Ciriano, Isidro, Mullally, Ann, and Hormoz, Sahand

Published
2022
Full Text
View/download PDF

41. Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Author

Januzzi, James L., Garasic, Joseph M., Kasner, Scott E., McDonald, Vickie, Petrie, Mark C., Seltzer, Jonathan, Mauro, Michael, Croce, Kevin, Berman, Ellin, Deininger, Michael, Hochhaus, Andreas, Pinilla-Ibarz, Javier, Nicolini, Franck, Kim, Dong-Wook, DeAngelo, Daniel J., Kantarjian, Hagop, Xu, Jing, Hall, Tracey, Srivastava, Shouryadeep, Naranjo, Daniel, and Cortes, Jorge

Published
2022
Full Text
View/download PDF

42. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Author

Januzzi, James L., Garasic, Joseph M., Kasner, Scott E., McDonald, Vickie, Petrie, Mark C., Seltzer, Jonathan, Mauro, Michael, Croce, Kevin, Berman, Ellin, Deininger, Michael, Hochhaus, Andreas, Pinilla-Ibarz, Javier, Nicolini, Franck, Kim, Dong-Wook, DeAngelo, Daniel J., Kantarjian, Hagop, Xu, Jing, Hall, Tracey, Srivastava, Shouryadeep, Naranjo, Daniel, and Cortes, Jorge

Published
2022
Full Text
View/download PDF

43. Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.

Author

Metzeler, Klaus H, primary, Platzbecker, Uwe, additional, Winer, Eric S., additional, Verma, Amit, additional, DeAngelo, Daniel J., additional, Severgnini, Mariano, additional, Choudhary, Gaurav S, additional, Zhao, Wanying, additional, Lane, Maureen E, additional, Gallagher, Cole, additional, Ferrari, Dora, additional, Masciarelli, Alyssa, additional, Von Roemeling, Reinhard W., additional, Carlisle, Samantha, additional, Nickle, David, additional, and Garcia-Manero, Guillermo, additional

Published
2024
Full Text
View/download PDF

44. Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m).

Author

Winer, Eric S., primary, Verma, Amit, additional, Groepper, Stefanie, additional, Gotze, Katharina S., additional, Abaza, Yasmin, additional, Mikesch, Jan-Henrik, additional, Choudhary, Gaurav S, additional, Masciarelli, Alyssa, additional, Zhao, Wanying, additional, Gallagher, Cole, additional, Von Roemeling, Reinhard W., additional, and DeAngelo, Daniel J., additional

Published
2024
Full Text
View/download PDF

45. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

Author

Daver, Naval Guastad, primary, Montesinos, Pau, additional, Altman, Jessica K., additional, Advani, Anjali S., additional, Wang, Eunice S., additional, Garciaz, Sylvain, additional, Martinelli, Giovanni, additional, Roboz, Gail J., additional, Walter, Roland B., additional, Begna, Kebede, additional, Lunghi, Monia, additional, Platzbecker, Uwe, additional, Vyas, Paresh, additional, Burke, Patrick William, additional, Curti, Antonio, additional, DeAngelo, Daniel J., additional, Gastaud, Lauris, additional, Schliemann, Christoph, additional, Oshrine, Benjamin, additional, and Sallman, David Andrew, additional

Published
2024
Full Text
View/download PDF

46. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.

Author

Jabbour, Elias, primary, Tholouli, Eleni, additional, Sandhu, Karamjeet S., additional, Shaughnessy, Paul, additional, Barba, Pere, additional, Guerreiro, Manuel, additional, Yallop, Deborah, additional, Logan, Aaron, additional, Abedi, Mehrdad, additional, Lao-Sirieix, Pierre, additional, Zhang, Yiyun, additional, Brugger, Wolfram, additional, Pule, Martin A., additional, Shah, Bijal D., additional, Bishop, Michael Russell, additional, Park, Jae H., additional, DeAngelo, Daniel J., additional, Peggs, Karl, additional, and Roddie, Claire, additional

Published
2024
Full Text
View/download PDF

48. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

Author

DeAngelo, Daniel J., Radia, Deepti H., George, Tracy I., Robinson, William A., Quiery, Albert T., Drummond, Mark W., and Bose, Prithviraj

Subjects
Mast cell disease -- Diagnosis -- Care and treatment -- Risk factors, Biological sciences, Health
Abstract

Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients with AdvSM. The primary endpoints were the maximum tolerated dose, recommended phase 2 dose and safety of avapritinib. Secondary endpoints included overall response rate and changes in measures of mast cell burden. Avapritinib was evaluated at doses of 30-400 mg once daily in 86 patients, 69 with centrally confirmed AdvSM. Maximum tolerated dose was not reached, and 200 mg and 300 mg daily were studied in dose-expansion cohorts. The most frequent adverse events observed were periorbital edema (69%), anemia (55%), diarrhea (45%), thrombocytopenia (44%) and nausea (44%). Intracranial bleeding occurred in 13% overall, but in only 1% of patients without severe thrombocytopenia (platelets In a phase 1 trial of patients with advanced systemic mastocytosis, avapritinib, a selective KIT inhibitor, was generally well tolerated, elicited durable clinical responses and led to reductions in mast cell disease burden., Author(s): Daniel J. DeAngelo [sup.1] , Deepti H. Radia [sup.2] , Tracy I. George [sup.3] , William A. Robinson [sup.4] , Albert T. Quiery [sup.5] , Mark W. Drummond [sup.6] [...]

Published
2021
Full Text
View/download PDF

49. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Author

Garcia, Jacqueline S., Kim, Haesook T., Murdock, H. Moses, Cutler, Corey S., Brock, Jennifer, Gooptu, Mahasweta, Ho, Vincent T., Koreth, John, Nikiforow, Sarah, Romee, Rizwan, Shapiro, Roman, Loschi, Fiona, Ryan, Jeremy, Fell, Geoffrey, Karp, Hannah Q., Lucas, Fabienne, Kim, Annette S., Potter, Danielle, Mashaka, Thelma, Stone, Richard M., DeAngelo, Daniel J., Letai, Anthony, Lindsley, R. Coleman, Soiffer, Robert J., and Antin, Joseph H.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results